
Compugen Ltd
NASDAQ:CGEN

Intrinsic Value
The intrinsic value of one
CGEN
stock under the Base Case scenario is
0.41
USD.
Compared to the current market price of 0.7 USD,
Compugen Ltd
is
Overvalued by 42%.
The Intrinsic Value is calculated as the average of the two valuation methods:

Fundamental Analysis
CGEN Profitability Score
Profitability Due Diligence
Compugen Ltd's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Score
Compugen Ltd's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
CGEN Solvency Score
Solvency Due Diligence
Compugen Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Score
Compugen Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Compugen Ltd
Current Assets | 86.1M |
Cash & Short-Term Investments | 83.3M |
Receivables | 2.4M |
Other Current Assets | 362k |
Non-Current Assets | 8.1M |
Long-Term Investments | 2.8M |
PP&E | 3.4M |
Other Non-Current Assets | 1.9M |
Current Liabilities | 11.9M |
Accounts Payable | 11M |
Accrued Liabilities | 613k |
Other Current Liabilities | 325k |
Non-Current Liabilities | 4.6M |
Other Non-Current Liabilities | 4.6M |
CGEN Capital Structure
Compugen Ltd
Market Capitalization | 60.6M USD | |
Total Debt | 0 USD | |
Minority Interest | 0 USD | |
Preferred Equity | 0 USD | |
Cash and Equivalents | 11.1M USD | |
Short-Term Investments | 72.3M USD | |
Enterprise Value | -22.7M USD |
Wall St
Price Targets
CGEN Price Targets Summary
Compugen Ltd
Shareholder Return
CGEN Return Decomposition
Main factors of price return
is not available
It is impossible to break down the market cap return as the net margin from 5 years ago is negative.
CGEN Price
Compugen Ltd
Average Annual Return | 41.01% |
Standard Deviation of Annual Returns | 110.35% |
Max Drawdown | -97% |
Market Capitalization | 60.6M USD |
Shares Outstanding | 86 624 643 |
Percentage of Shares Shorted | 3.59% |
Company Profile


Country
Industry
Market Cap
Dividend Yield
Description
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Contact
IPO
Employees
Officers
The intrinsic value of one
CGEN
stock under the Base Case scenario is
0.41
USD.
Compared to the current market price of 0.7 USD,
Compugen Ltd
is
Overvalued by 42%.